LRMR

Conviction 29HealthcareScan · Mon, Sep 28, 2026

Larimar Therapeutics, Inc. (LRMR) closed at $3.18 (+3.25%) on Sep 28, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 32, RS Rating 26, -46.6% from its 52-week high, -8.5% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

LRMR$3.18+3.25%

ResistanceSupportVol 14Insider buy

Vol MA14 1.64M

Jun 30Jul 17Aug 5Aug 21Sep 10Sep 28

Larimar Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.larimartx.com ↗

Price3.18

Change+3.25%

Gap-0.16%

Rel volume1.16×

Avg volume1.37M

Avg $ vol5.04M

SMA 203.77

SMA 503.95

SMA 2003.94

Price vs 50-19.54%

Price vs 200-19.50%

MA stackmixed

50/200 cross—

Supertrenddown · 3.83

RSI (14)32

MACD hist-0.08

MACD cross—

Stoch %K / %D13 / 7

ADX (14)18

+DI / −DI15 / 33

RSI divergence—

MACD divergence—

ATR %7.20%

ADR %5.95%

52w high5.95

52w low2.81

From 52w high-46.64%

Above 52w low+12.99%

New 52w highNo

SqueezeOff

Bollinger width26.89%

%B-0.08

Donchian pos13.48%

Donchian high4.17

Donchian low3.02

AVWAP (52w high)4.39

vs AVWAP high-27.67%

AVWAP (52w low)4.28

vs AVWAP low-25.87%

OBV trendFlat

Chaikin MF (20)-0.18

Today vs 20d1.16×

Avg vol (14d)1.64M

Avg vol (20d)1.37M

Avg $ vol (20d)5.04M

Market cap329.83M

RS Rating26 / 99

RS 3m (vs SPY)-4.09%

RS 6m (vs SPY)-52.00%

RS line new highNo

Trend template2/8

Technical rank17.4

1 week-17.10%

1 month-21.60%

3 months-0.78%

6 months-31.28%

1 year-34.67%

YTD-8.50%

P/E-1.99

P/B2.59

P/S—

P/FCF-2.91

EPS-1.32

Div yield—

ROE-130.06%

ROA-100.22%

Debt/Eq0.11

Current4.70

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-105.54%

Price target12.43

Target upside291.50%

Analyst ratingBuy

Institutional95.38%

Ent. value251.69M

Revenue0

Net income-32.78M

Gross profit—

Free cash flow-113.29M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out103.88M

Employees71

ListedFri, May 29, 2020

Free float61.69M

Float %59.4%

Short interest13.72M

Days to cover15.3d

Short volume73.1%

Squeeze score87 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.30 vs −$0.39

Last surprise+23.1% beat

Setup gradeD

Conviction29 / 100

Pattern quality—

Tech rank17.4 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance4.39

Support3.71

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in LRMR

All disclosures →

No recent disclosed trades by Congress in LRMR. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in LRMR · open-market 1 buy

Insider	Side	Shares	Value	Traded	Filed
Hamilton Thomas Edward Director · Common Stock · 2026-07-06	Buy	50K	$167K	2026-07-06	2026-07-08
Hamilton Thomas Edward Director · Stock Option (Right to Buy) · 2026-05-19	Grant	55.15K	$0	2026-05-19	2026-05-20
SHERMAN JEFFREY W Director · Stock Option (Right to Buy) · 2026-05-19	Grant	55.15K	$0	2026-05-19	2026-05-20
DEERFIELD MANAGEMENT COMPANY, L.P. Director · Stock Option (Right to Buy) · 2026-05-19	Grant	55.15K	$0	2026-05-19	2026-05-20
THOMAS FRANK E Director · Stock Option (Right to Buy) · 2026-05-19	Grant	55.15K	$0	2026-05-19	2026-05-20
Flynn James E Director · Stock Option (Right to Buy) · 2026-05-19	Grant	55.15K	$0	2026-05-19	2026-05-20
Truitt Joseph Director · Stock Option (Right to Buy) · 2026-05-19	Grant	55.15K	$0	2026-05-19	2026-05-20
LEFF JONATHAN S Director · Stock Option (Right to Buy) · 2026-05-19	Grant	55.15K	$0	2026-05-19	2026-05-20

SEC filings

EDGAR filings in LRMR · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.